News

Press Releases

Year: 2012 | 2011 | 2010 | 2009 | 2008

May 3, 2012	Genzyme Announces Regulatory Approvals of Expanded Waterford, Ireland Manufacturing Plant
April 24, 2012	Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif® in Phase III Trial
April 20, 2012	Genzyme Demonstrates Depth of MS Pipeline at AAN with Results from Multiple Sclerosis Phase lll Trials
April 19, 2012	Genzyme’s Biologics Support Center Achieves LEED Gold Rating for Environmentally Responsible Design
April 16, 2012	Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis
March 29, 2012	Genzyme and Isis Announce Submission of U.S. NDA for KYNAMRO™ (mipomersen sodium) in Homozygous Familial Hypercholesterolemia
March 29, 2012	KYNAMRO™ (mipomersen sodium) Data Presented at XVI International Symposium on Atherosclerosis
March 1, 2012	Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant
February 29, 2012	Genzyme Recognizes International Rare Disease Day with Second Annual Patient Advocacy Grant Program
February 23, 2012	Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
February 8, 2012	Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints
January 24, 2012	Genzyme Announces FDA Approval of Framingham Manufacturing Plant
January 20, 2012	Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
January 18, 2012	Genzyme Announces European Approval of Framingham Manufacturing Plant

Terms and Conditions of Use | Privacy Policy | © 2002-2012 Genzyme Corporation, a Sanofi company. All rights reserved.